Janssen Gets Positive CHMP Opinion on Expanded Use of Imbruvica

Date : 06/28/2019 @ 1:49PM
Source : Dow Jones News
Stock : Johnson and Johnson (JNJ)
Quote : 132.84  0.0 (0.00%) @ 2:26PM

Janssen Gets Positive CHMP Opinion on Expanded Use of Imbruvica

Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart

6 Months : From Apr 2019 to Oct 2019

Click Here for more Johnson and Johnson Charts.

By Michael Dabaie


Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos. said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended broadening the existing marketing authorization for Imbruvica, or ibrutinib, in two indications.

One recommendation is for the use of ibrutinib in combination with obinutuzumab in adult patients with previously untreated chronic lymphocytic leukemia. The second is for use of ibrutinib plus rituximab for the treatment of adult patients with Waldenstrom's macroglobulinemia.

Both positive opinions will now be reviewed by the European Commission, which has the authority to grant final approval of the indications.


Write to Michael Dabaie at michael.dabaie@wsj.com


(END) Dow Jones Newswires

June 28, 2019 08:34 ET (12:34 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest JNJ Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.